Disability progression in multiple sclerosis is associated with plasma neuroactive steroid profile

Christopher C. Cheng(University of Alberta), Christopher Power(University of Alberta), Daniela Gómez(University of Alberta), Fabrizio Giuliani(University of Alberta), Jennifer A. McCombe(University of Alberta), Penelope Smyth(University of Alberta), Glen B. Baker(Women and Children’s Health Research Institute), Gregg Blevins
Neurological Sciences
April 8, 2021
10.1007/s10072-021-05203-4
Cited by 7

Related Papers

Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
|Nature Medicine|2007|1.8k
International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors
|Pharmacological Reviews|2013|849
The Role of Inflammation in Depression and Fatigue
|Frontiers in Immunology|2019|651
The promise of minocycline in neurology
|The Lancet Neurology|2004|521
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
|The Lancet Neurology|2018|345